Actuate Therapeutics (NASDAQ:ACTU) Given “Buy” Rating at HC Wainwright

Actuate Therapeutics (NASDAQ:ACTU)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $20.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 227.87% from the stock’s previous close.

A number of other analysts also recently commented on the company. Wall Street Zen upgraded Actuate Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Actuate Therapeutics in a research note on Thursday, November 13th. Finally, B. Riley began coverage on shares of Actuate Therapeutics in a research report on Tuesday, August 26th. They set a “buy” rating and a $20.00 target price for the company. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $20.33.

Actuate Therapeutics Stock Performance

Shares of Actuate Therapeutics stock opened at $6.10 on Wednesday. Actuate Therapeutics has a one year low of $5.47 and a one year high of $11.99. The company has a market cap of $141.78 million, a P/E ratio of -7.01 and a beta of -0.23. The firm has a fifty day moving average of $6.88 and a two-hundred day moving average of $7.69.

Actuate Therapeutics (NASDAQ:ACTU) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.02.

Institutional Trading of Actuate Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ACTU. BIOS Capital Management LP lifted its stake in shares of Actuate Therapeutics by 0.9% during the 3rd quarter. BIOS Capital Management LP now owns 10,049,996 shares of the company’s stock worth $67,234,000 after purchasing an additional 84,917 shares during the period. Vanguard Group Inc. increased its stake in Actuate Therapeutics by 19.5% in the third quarter. Vanguard Group Inc. now owns 316,010 shares of the company’s stock valued at $2,114,000 after purchasing an additional 51,546 shares during the last quarter. Bank of America Corp DE lifted its position in Actuate Therapeutics by 61,068.0% during the second quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock worth $93,000 after buying an additional 15,267 shares during the period. Voss Capital LP lifted its position in Actuate Therapeutics by 101.0% during the second quarter. Voss Capital LP now owns 286,140 shares of the company’s stock worth $1,748,000 after buying an additional 143,759 shares during the period. Finally, New York State Common Retirement Fund acquired a new stake in Actuate Therapeutics in the 2nd quarter worth about $105,000.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.